HPV vaccination coverage for pediatric, adolescent and young adult patients receiving care in a childhood cancer survivor program

Lauren Thomaier, Danielle A. Aase, Rachel I. Vogel, Helen M. Parsons, Karim T. Sadak, Deanna Teoh

Research output: Contribution to journalArticlepeer-review

Abstract

Pediatric, adolescent and young adult patients undergoing cancer treatment and/or hematopoietic stem cell transplant are at increased risk for developing a secondary human papillomavirus (HPV)-associated malignancy. The objective of this study was to determine HPV vaccination coverage among individuals participating in a childhood cancer survivor program (CCSP). A retrospective cohort study was conducted among CCSP patients age 11–26 years attending a CCSP visit between 2014 and 2019. Survivors were age-, sex-, and race-matched 1:2 with controls without cancer. Data were abstracted from the electronic health record and state-based vaccination registry. Analysis was limited to Minnesota residents to minimize missing vaccination data. Survivorship care plans (SCPs) were reviewed for vaccine recommendations. 592 patients were included in the analyses (200 CCSP patients; 392 controls). By study design, mean age (18.4 years), race (72 % white), and sex (49 % female) were similar in the two groups. Among CCSP patients 22 % resided in a rural area compared to 3.8 % of controls. Vaccination coverage among CCSP patients was not statistically significantly different from controls [60.0 % vs 66.3 %, OR = 0.82, 95 % CI: (0.55, 1.23), p = 0.35]. Completion of 3 doses was not different between groups even though 3 doses is recommended for all CCSP patients regardless of age at initiation (28.5 % vs 30.1 %, p = 0.09). Only 8.0 % of SCPs recommended HPV vaccination. Although patients participating in a CCSP did not have significantly different HPV vaccination coverage compared to controls, HPV vaccination initiation and 3-dose series completion are still suboptimal in a patient population at high-risk of a secondary HPV-associated cancer.

Original languageEnglish (US)
Article number101972
JournalPreventive Medicine Reports
Volume29
DOIs
StatePublished - Oct 2022

Bibliographical note

Funding Information:
This work was supported by the Agency for Healthcare Research and Quality [Grant No R03HS026982], the National Institute of Health’s National Center for Advancing Translational Sciences [Grant UL1TR002494], and the Masonic Cancer Center [Grant P30 CA77598]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health’s National Center for Advancing Translational Sciences, Agency for Healthcare Research and Quality, or the Masonic Cancer Center.

Publisher Copyright:
© 2022 The Author(s)

Keywords

  • Adolescent
  • HPV vaccination
  • Pediatric
  • Secondary cancer prevention
  • Survivorship
  • Young adult cancer survivors

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'HPV vaccination coverage for pediatric, adolescent and young adult patients receiving care in a childhood cancer survivor program'. Together they form a unique fingerprint.

Cite this